ClinicalTrials.Veeva

Menu

Irinotecan, Gemcitabine and Radiation Therapy for Pancreatic Cancer

R

Rambam Health Care Campus

Status and phase

Completed
Phase 3
Phase 2

Conditions

Pancreatic Cancer

Treatments

Drug: irinotecan, gemcitabine

Study type

Interventional

Funder types

Other

Identifiers

NCT00192712
RonIrinoGem.CTIL

Details and patient eligibility

About

The study hypothesis is that chemoradiation based on 2 drugs will improve local control and long-term survival in patients with locally advanced pancreatic cancer. That is why gemcitabine and irinotecan are combined in an induction phase of 2 months and then this IrinoGem combination is given for 3 more cycles, in reduced doses,concurently with irradiation.

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • locally advanced pancreatic cancer
  • performance status 0-2
  • normal blood count and chemistry
  • no previous chemotherapy or radiotherapy

Exclusion criteria

  • serious concurrent systemic disease

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems